Review papers with raw data transparency

What the review does well

• Comprehensive collation of RNF2-focused primary studies across diverse cancers and mechanisms (histone H2AK119ub, interactions with SIK1, p53, TXNIP, CCND2, LTBP2/TGFβ; radiosensitization/chemosensitization contexts) Yan et al., RNF2 review summary.
• Highlights specific mechanistic primary studies (e.g., RNF2 → CCND2/LTBP2 in melanoma; RNF2 → SIK1 in HCC; RNF2 → p53 in ovarian), allowing readers to follow to original experimental data Rai et al., melanomaQu & Qu, HCC.

Primary weaknesses, biases, and blindspots

• Narrative-review format: no systematic search strategy or PRISMA-style flow; selection bias and publication bias are not quantified — reviewers cannot tell how negative/neutral RNF2 studies were treated (risk of positive-result bias).
• Heterogeneity of evidence: many cited experiments are cell-line–based or small tissue-cohort IHC studies; few large, independent clinical cohorts or prospective validations are provided (limits translational claims) Yan et al., limitations.
• Context-dependence underappreciated: RNF2 can have dual/contrasting roles across tissues (e.g., promoting proliferation in some contexts while affecting radiosensitivity via DNA-damage signaling in others). The review notes this but does not formalize context modifiers (mutational landscape, p53 status, BAP1 status, PRC1 composition) that determine directionality.
• Conflict-of-interest and funding: authors disclose national funding (NSFC, Anhui); no COIs declared — still, the review does not include an assessment of potential sponsor-related bias across cited primary studies (common blindspot).

Key mechanistic claims and supporting primary evidence (select examples)

1. Melanoma: RNF2 promotes proliferation via CCND2 activation and metastasis via H2AK119ub-mediated repression of LTBP2 (thus activating TGFβ). Evidence: tissue microarrays, IHC, shRNA/overexpression, promoter ChIP and rescue experiments (Rai et al.) Rai et al., melanoma mechanism.
2. Hepatocellular carcinoma (HCC): RNF2 amplification (~19.7% in study) downregulates SIK1 by direct interaction; RNF2 knockdown reduces proliferation and metastasis in vitro/in vivo (Qu & Qu) Qu & Qu, HCC SIK1.
3. Breast cancer: RNF2 sustains p-FAK via p63/Hsp70 axis; RNF2 depletion reduces invasion (Bosch et al.) — evidence from IHC, TMA, promoter ChIP, and functional assays Bosch et al., breast RNF2.
4. Ovarian cancer/chemoresistance: RNF2 modulated by microRNAs (e.g., miR-139-5p) and MAPK pathway affects cisplatin resistance; RNF2 knockdown or miR overexpression can sensitize (Chen et al., 2018) Chen et al., ovarian chemoresistance.

Translational claims — realism check

• Biomarker potential: multiple small to moderate cohort IHC studies (e.g., UCB 184 specimens) show prognostic association with OS/CSS; promising but requires: (a) independent multi-center validation; (b) standardized assay (IHC scoring/H-score) and cutoffs; (c) evaluation vs established markers (e.g., PSA in prostate) Li et al., UCB prognostic study.
• Targeting RNF2 therapeutically: conceptually attractive (E3 ligase enzymatic activity; epigenetic rewiring), but direct small-molecule RNF2 inhibitors are not clinically validated; alternative strategies (epigenome editing with dCas9 effectors, CRISPR knockout, or indirect upstream pathway modulation) remain preclinical and face delivery/specificity challenges. The review's CRISPR therapeutic suggestions are forward-looking but speculative, given current delivery and safety limitations Konermann et al., CRISPR epigenome editing.

Critical recommendations / what would strengthen the claims

1. Systematic evidence synthesis: a PRISMA-aligned systematic review + meta-analysis of RNF2 expression effect sizes (IHC H-score, mRNA fold change) across comparable cohorts would quantify heterogeneity, effect magnitude, and publication bias.
2. Large-scale clinical validation: multi-center cohorts (TCGA-level or prospective tissue banks) with standardized assays and covariate-adjusted survival models to test RNF2 as independent prognostic biomarker.
3. Mechanistic rigor: orthogonal in vivo models (conditional RNF2 ablation in tumor lineages; transgenic expression) coupled with rescue experiments (catalytically dead RNF2 mutants; target gene rescue) to define when RNF2 acts via H2AK119ub vs non-canonical routes.
4. Therapeutic feasibility studies: (i) development/characterization of small molecules or PROTACs that modulate RNF2 activity/stability; (ii) delivery-competent epigenome-editing studies (AAV/lipid nanoparticle) with off-target and safety profiling.

Suggested targeted experiments (concise)

1. CRISPR conditional RNF2 knockout in patient-derived xenografts (PDX) for two cancers with differing RNF2 roles (melanoma vs glioma/glioblastoma models) to test tumor growth, metastasis, and therapy response; include catalytically-dead RNF2 rescue.
2. Large-cohort IHC study (n > 500) across multiple centers with pre-specified H-score cutoffs and multivariable Cox models to validate prognostic value, including interaction tests with p53/BAP1/EZH2 status.

Confidence, limitations, and falsifiability

Overall, the review assembles solid fragmentary evidence that RNF2 is frequently dysregulated in cancer and can act as an oncogenic promoter in several contexts, but confidence in clinical utility is moderate at best until larger, reproducible cohort-level validations and rigorous causal in vivo experiments are completed. The RNF2-cancer hypothesis is falsifiable by (a) showing no independent prognostic effect in large, adjusted cohorts, and (b) by demonstrating that RNF2 loss-of-function does not alter tumor phenotypes in well-powered in vivo models.

Direct primary-citation anchors (for quick follow-up)

• Rai et al., melanoma
• Qu & Qu, HCC
• Bosch et al., breast
• Su et al., p53

Bottom-line (concise): Yan et al. collates convincing, tissue-specific preclinical evidence that RNF2 contributes to oncogenic programs in multiple cancers, but translational claims (biomarker/therapy) need prospective, multi-center validation and deeper causal in vivo experiments before clinical application.

Selected citations used in this review (clickable anchors above)

• Yan et al., RNF2 review
• Rai et al., melanoma
• Qu & Qu, HCC
• Bosch et al., breast
• Su et al., p53